Abstract:Mounting evidence underscores the intricate interplay between the immune system and skeletal muscles in Duchenne muscular dystrophy (DMD), as well as during regular muscle regeneration. While immune cell infiltration into skeletal muscles stands out as a prominent feature in the disease pathophysiology, a myriad of secondary defects involving metabolic and inflammatory pathways persist, with the key players yet to be fully elucidated. Steroids, currently the sole effective therapy for delaying onset and symptom control, come with adverse side effects, limiting their widespread use. Preliminary evidence spotlighting the distinctive features of T cell profiling in DMD prompts the immuno-characterization of circulating cells. A molecular analysis of their transcriptome and secretome holds the promise of identifying a subpopulation of cells suitable as disease biomarkers. Furthermore, it provides a gateway to unraveling new pathological pathways and pinpointing potential therapeutic targets. Simultaneously, the last decade has witnessed the emergence of novel approaches. The development and equilibrium of both innate and adaptive immune systems are intricately linked to the gut microbiota. Modulating microbiota-derived metabolites could potentially exacerbate muscle damage through immune system activation. Concurrently, genome sequencing has conferred clinical utility for rare disease diagnosis since innovative methodologies have been deployed to interpret the functional consequences of genomic variations. Despite numerous genes falling short as clinical targets for MD, the exploration of Tdark genes holds promise for unearthing novel and uncharted therapeutic insights. In the quest to expedite the translation of fundamental knowledge into clinical applications, the identification of novel biomarkers and disease targets is paramount. This initiative not only advances our understanding but also paves the way for the design of innovative therapeutic strategies, contributing to enhanced care for individuals grappling with these incapacitating diseases.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore new biomarkers and treatment targets in Duchenne Muscular Dystrophy (DMD), in order to promote the understanding of DMD and design innovative treatment methods, thereby improving the level of patient care. Specifically, the paper focuses on the following aspects: 1. **Interaction between the immune system and skeletal muscle**: The paper emphasizes the important role of the immune system in DMD, especially the phenomenon of immune cell infiltration in the pathophysiology of the disease. At the same time, the paper points out that many secondary defects in metabolic and inflammatory pathways have not been fully elucidated. 2. **Limitations of existing treatments**: Currently, the only effective therapy for delaying disease progression and controlling symptoms is steroids, but its side effects limit its wide use. 3. **Preliminary evidence of T - cell characteristics**: Preliminary studies have shown that the characteristics of T - cells in DMD patients are different, which prompts researchers to further conduct immunophenotyping, especially by analyzing the transcriptome and secretome of circulating cells to identify cell subsets that may serve as disease biomarkers. 4. **Role of the microbiome**: Research in the past decade has shown that the development and balance of the innate and adaptive immune systems are closely related to the gut microbiome. Modulating microbiome - derived metabolites may exacerbate muscle damage by activating the immune system. 5. **Application of genomic sequencing**: The development of genomic sequencing technology has provided clinical utility for the diagnosis of rare diseases, especially in explaining the functional consequences of gene variations. Although many genes have not become clinical targets for MD, exploring "dark genes" (Tdark genes) may reveal new treatment insights. 6. **Identification of biomarkers**: In order to accelerate the translation of basic research into clinical applications, it is crucial to identify new biomarkers and disease targets. This not only helps to deepen the understanding of disease mechanisms, but also provides support for designing innovative treatment strategies. In summary, this paper aims to promote the clinical treatment progress of DMD by comprehensively analyzing data on the immune system, metabolic pathways, microbiome, and genome, etc., to discover new biomarkers and treatment targets.

Advancing Biomarker Discovery and Therapeutic Targets in Duchenne Muscular Dystrophy: A Comprehensive Review